events that she might blame for her misfortune. The other control group was the Collaborative Perinatal Project population. Although these women had been interviewed during pregnancy and so had not had as much time as the other controls to forget, they too lacked the incentive the cases’ mothers had to recall events in early pregnancy, and being a relatively underprivileged group (55% Black or Puerto Rican) they are less likely to have ever known what their body temperature was during any fever.

Secondly, Miller et al. suggest that published work favours the view that local outbreaks of febrile illness and of anecaphaly tend to be associated—but both of the four papers they cite in this connection1,2 only mention associations involving about four anecaphalics each, and the other two6,4 do not mention epidemics of febrile illness at all but deal exclusively with increases in the frequency of neural-tube defects which lasted several years. No mention is made of other published work in which several very large series of live and still births occurring 26–40 weeks after influenza epidemics (including well over a thousand anecaphalics in all) were compared with births in the same places at other times in respect of the frequency of various malformations—with results that were completely negative for anecaphalies.6,7

Another population that seems to be at increased risk of hyperthermia but not of anecaphaly is that of Finland, the home of the sauna, where less than 0·6/1000 births were reported to be anecaphalic.8

Especially in the light of the research on other species cited by Miller et al., their hypothesis that hyperthermia can cause anecaphaly in man may merit further testing; but the above features of their control groups and of the population studies cited make this hypothesis less convincing than Miller et al. suggest.

Department of Community Medicine, University of Manchester, Manchester M13 9PT

IAN LECK

PLASMAPHERESIS IN RAYNAUD’S DISEASE

SIR,—Dr Talpos and his colleagues (Feb. 25, p. 416) report dramatic improvement after plasmapheresis in four cases of Raynaud’s phenomenon with ulceration of the digits. Since this syndrome is seen in a heterogeneous group of conditions of which sclerodactyly with telangiectasia and calcinosis (c.r.s.t. syndrome)9 is perhaps the most common, it would be interesting if the authors could comment on the results of this treatment in all the other conditions in which Raynaud’s phenomenon is present. Although these women had been interviewed during pregnancy and had no recall of events in early pregnancy, and being a relatively underprivileged group (55% Black or Puerto Rican) they are less likely to have ever known what their body temperature was during any fever.

The nomenclature of small-vessel disease of the extremities is confused. The terms Raynaud’s disease and Raynaud’s phenomenon are often used interchangeably, and some writers attempt to divide them into primary and secondary to classify better the clinical signs we so easily recognise. All five patients have minor increase of at least one of the three immunoglobulins which we measure (IgA, IgG, and IgM). These increases average about 15% above the upper limit of normal with a maximum increment of less than twice normal. Caution is necessary in interpreting this, however, because we have not determined what abnormalities, if any, would be present in a group of matched patients with cutaneous ulcers but without Raynaud’s symptoms. Other routine tests have been unremarkable.

Clinicallly the five patients are slowly regressing to their pretreatment state, although they all are much improved. One patient with scleroderma who underwent plasmapheresis last summer for pregangrenous changes of an entire index finger eventually lost a small amount of finger pulp. She had a further three plasma exchanges, all averaging 70% total plasma volume, when her index finger began to deteriorate with the winter cold. Since then her condition has stabilised. The clinical course of these patients leads us to believe that plasmapheresis is a valuable form of therapy for certain patients. Better treatment will be forthcoming when the mechanism for the efficacy of this therapy has been elucidated. We hope to answer some of these questions at the conclusion of our formal trial.

Deborah of Biomedical Engineering and Haematology, King’s College Hospital Medical School, London SE5 8RX, and Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.

G. B. TALPOS
L. T. COTTON
J. M. WHITE
M. HORBROCKS

IMMUNE COMPLEXES AND PROGNOSIS OF HUMAN BREAST CANCER

SIR,—We have found4 that sequential determination of circulating immune complexes (c.i.c.) confirms the clinicopathological prognosis in breast cancer. In patients with good prognosis (no lymph-node involvement detectable at mastectomy) c.i.c. values fell to normal range twelve months after the operation whilst the c.i.c. value remained high in patients with poor prognosis (metastases in axillary lymph-nodes at mastectomy) and in those who died from cancer within 22 months of the operation.

We now have results on 83 patients and have found a similar pattern of c.i.c. values varying according to clinicopathological prognosis or death (figure a).

When c.i.c. levels were evaluated by outcome (dead or alive) 12–48 months after mastectomy (figure b) the correlation with prognosis assessed clinicopathologically had disappeared. By contrast, patients both with good and poor prognosis who are still alive displayed preoperatively similar c.i.c. levels which decreased postoperatively to almost normal levels. Patients who died during the follow-up period, had, both preoperatively and postoperatively, c.i.c. levels (p<0·05) significantly higher than those of the survivors. Again, there was no difference between patients with good and poor prognosis. Furthermore, the postoperative decrease in c.i.c. was not significant.

Figure c covers patients followed up for 24 months after mastectomy and those of intermediate prognosis (metastases in apical axillary and/or internal mammary lymph-nodes at mastectomy) and in those who died from cancer within 22 months of the operation.

We have found2 that sequential determination of circulating immune complexes (c.i.c.) confirms the clinicopathological prognosis in breast cancer. In patients with good prognosis (no lymph-node involvement detectable at mastectomy) c.i.c. values fell to normal range twelve months after the operation whilst the c.i.c. value remained high in patients with poor prognosis (metastases in axillary lymph-nodes at mastectomy) and in those who died from cancer within 22 months of the operation.

We now have results on 83 patients and have found a similar pattern of c.i.c. values varying according to clinicopathological prognosis or death (figure a). When c.i.c. levels were evaluated by outcome (dead or alive) 12–48 months after mastectomy (figure b) the correlation with prognosis assessed clinicopathologically had disappeared. By contrast, patients both with good and poor prognosis who are still alive displayed preoperatively similar c.i.c. levels which decreased postoperatively to almost normal levels. Patients who died during the follow-up period, had, both preoperatively and postoperatively, c.i.c. levels (p<0·05) significantly higher than those of the survivors. Again, there was no difference between patients with good and poor prognosis. Furthermore, the postoperative decrease in c.i.c. was not significant.

Figure c covers patients followed up for 24 months after mastectomy and those of intermediate prognosis (metastases only in lower axillary lymph-nodes); patients given chemotherapy within 12 months of mastectomy have been excluded because this treatment reduces c.i.c. levels in animals. (unpublished). Regardless of clinicopathological staging, patients who
